Answers are grounded in this paper and cite their sources.
Chronic levodopa treatment of 22 patients with Parkinson's disease was supplemented with methyldopa, an inhibitor of dopa decarboxylase, in doses from 125 to 750 mg. daily. Improvement in maior parameters of Parkinson's disease was seen in 14 patients, 10 of whom had had troublesome fluctuations in response to levodopa. Seven patients were still improved after 20 weeks. Methyldopa worsened dyskinesia in 14 patients, did not affect nausea, and was associated with agitation in 6 patients. Blood pressure did not change significantly. Although inhibition of dopa decarboxylase is methyldopa's most likely mechanism of action, methylated metabolites may also play a role. Methyldopa is a tolerable adiunct to levodopa therapy for Parkimon's disease for patients with rapid fluctuations in motor status.
No takes yet. Share an insight, caveat, or question.
Sweet et al. (1972) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: